H1N1INFLUENZAVIRUS.US

Novavax, Inc. (Nasdaq: NVAX) announced that the enrollment of over 3,500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus-like-particle (VLP) pandemic influenza vaccine study. With the 1,000 subjects already enrolled in Stage A of the trial, the enrollment in this pivotal trial is now complete with over 4,500 subjects. In this Stage B of Novavax’s pivotal study of …

Read more:
NOVAVAX Completes Enrollment Of Pivotal H1N1 Influenza Vaccine Clinical Trial In Mexico (Medical News Today)

Novavax, Inc. (Nasdaq: NVAX) announced that the enrollment of over 3500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus -like-particle (VLP) pandemic influenza vaccine study. With the 1000 subjects already …

Link:
NOVAVAX Completes Enrollment Of Pivotal H1N1 Influenza Vaccine …

Novavax, Inc. (Nasdaq: NVAX ) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.

More here:
Novavax Reports Additional Positive Data From Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study In Healthy … (BioresearchOnline)

Novavax, Inc. (Nasdaq: NVAX ) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.

Read the original:
NOVAVAX Reports Additional Positive Data From Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study In Healthy … (PharmaceuticalOnline)

ROCKVILLE, Md., Feb. 8 /PRNewswire-FirstCall/ — Novavax, Inc. (Nasdaq: NVAX) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.

Read the original:
NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy … (redOrbit)

… Inc. (Nasdaq: NVAX) announced today that it has initiated a two-stage clinical study of its virus -like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare. …

View post:
Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine …

Novavax, Inc. (Nasdaq: NVAX) announced that enrollment has been completed in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus-like-particle (VLP) pandemic influenza unadjuvanted vaccine in the country of Mexico.

See the original post here:
NOVAVAX Completes First Stage Of Enrollment In Pivotal H1N1 Influenza Vaccine Study In The Country Of Mexico (Medical News Today)

Novavax, Inc. (Nasdaq: NVAX ) announced today that enrollment has been completed in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus-like-particle (VLP) pandemic influenza unadjuvanted vaccine in the country of Mexico.

Go here to read the rest:
NOVAVAX Completes First Stage Of Enrollment In Pivotal H1N1 Influenza Vaccine Study In The Country Of Mexico (PharmaceuticalOnline)

Rockville, MD/PRNewswire-FirstCall/ — Novavax, Inc. (Nasdaq: NVAX ) announced today that enrollment has been completed in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus -like-particle (VLP) pandemic influenza …

Read the original post:
NOVAVAX Completes First Stage Of Enrollment In Pivotal H1N1 Infl

Novavax, Inc. (NASDAQ: NVAX) is trading higher after it announced that it began a two-stage clinical study of its virus-like particle H1N1 influenza vaccine in Mexico….

Read more here:
Novavax-GE/Avimex Pact Interest (NVAX)